Dog /

Breed profile · FDA CVM July 2026 extract

Spaniel - King Charles adverse-event record

Adverse-event filings for Spaniel - King Charles (Dog) in the FDA Center for Veterinary Medicine openFDA extract. Browse dog breeds, reactions, and outcomes below.

#139 of 510
by report volume (all breeds)
525
FDA CVM reports on file
3.0%
death-coded share of reports
#234 of 275
by death-coded share (≥50 reports)

How the 525 reports break down

By recorded gender -- every report on file for Spaniel - King Charles, no filtering.

Annual report volume

Annual adverse-event report trend Yearly FDA CVM adverse-event report counts for this breed. 45 33.75 22.5 11.25 0 2019 2020 2021 2022 2023 2024 2025 2026 Reports filed Death-coded reports
Annual report volume for Spaniel - King Charles drawn from FDA CVM filings.

Data updated September 2026

The verdict

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Spaniel - King Charles ranks #139 of 510 by total reports (525) and #234 of 275 by death-coded share (3.0%). National dual: Retriever - Labrador is #1 of 510 by total adverse-event reports (93,675) at death-coded-share rank 195 of 275 breeds with at least 50 reports (3.7%); separately, Atlantic Salmon (Salmo salar) is #1 highest death-coded share at 99.0% (report rank #233).

93,675
Retriever - Labrador reports (#1)
99.0%
Atlantic Salmon (Salmo salar) death share (#1)
#139
This breed, reports of 510
#234
This breed, death share of 275

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Spaniel - King Charles has 525 reports now versus 520 in that prior snapshot: 5 more (1.0%).

Report change
+5
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Spaniel - King Charles changes

Total Reports

525

Above-median volume

Deaths Reported

16

of 525 reports

Death-coded share of reports

3.0%

Lowest death-coded share

Avg Age at Report

5.0 yr

9.0 kg avg weight

Breed Safety Scorecard

A+ (91/100)

A weighted composite across 4 of 4 dimensions, each benchmarked against every tracked breed with at least 200 reports (n=185). Dimensions with insufficient data drop out and their weight redistributes to the rest, so a missing input never silently deflates the score.

Death rate A
3.0%

Share of reports coded as a fatality

Euthanasia rate A+
0.8%

Share of reports resulting in euthanasia

Full recovery rate A+
50.3%

Share of reports coded "Recovered/Normal"

5-year trend A-
-53%

Change in annual report volume over the last 5 complete years

Death-Coded Outcome Share

Spaniel - King Charles death-coded reports 3.0%
Cross-breed median

3.0% of 525 spaniel - king charles reports involved a death outcome.

How to read this number

Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.

Where Spaniel - King Charles's death-coded share sits among indexed breeds

Death-coded share of FDA CVM reports, breeds with ≥50 reports (July 2026 extract)

3% 15th percentile Higher share than 15% of 275 indexed breeds

5%–10%: 1 indexed breeds (0%). This entry sits in this band. 20%–25%: 2 indexed breeds (1%). Above this entry. 25%–30%: 3 indexed breeds (1%). Above this entry. 30%–35%: 4 indexed breeds (1%). Above this entry. 35%–40%: 5 indexed breeds (2%). Above this entry. 40%–45%: 6 indexed breeds (2%). Above this entry. 45%–50%: 3 indexed breeds (1%). Above this entry. 50%–55%: 7 indexed breeds (3%). Above this entry. 55%–60%: 7 indexed breeds (3%). Above this entry. 60%–65%: 21 indexed breeds (8%). Above this entry. 65%–70%: 11 indexed breeds (4%). Above this entry. 70%–75%: 15 indexed breeds (5%). Above this entry. 75%–80%: 13 indexed breeds (5%). Above this entry. 80%–85%: 11 indexed breeds (4%). Above this entry. 85%–90%: 12 indexed breeds (4%). Above this entry. 90%–95%: 12 indexed breeds (4%). Above this entry. 95%–100%: 142 indexed breeds (52%). Above this entry. Spaniel - King Charles 5% 100% every breed with ≥50 FDA reports, bucketed by value

Each bar is a band; taller bars hold more indexed breeds. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source FDA Center for Veterinary Medicine, openFDA adverse event extract (PlainBreed) · July 2026 extract

This histogram uses the same ≥50-report cohort as the highest death-coded share ranking. A higher share means more of this breed's reported events were death-coded, not a mortality rate for living animals.

Average weight at time of report: 9.0 kg (19.8 lbs)

Top Reported Reactions

Vomiting 121
Emesis 81
Lethargy (see also Central nervous system depression in 'Neurological') 77
Diarrhoea 68
Digestive tract disorder NOS 36
Lack of efficacy - NOS 29
Lack of efficacy (ectoparasite) - flea 28
Seizure NOS 28

Most Referenced Drugs

Milbemycin Oxime + Spinosad 142
Ivermectin + Pyrantel As Pamoate Salt 70
Afoxolaner 65
Spinosad 46
Fluralaner Chew Tablets 25
Pimobendan 21
Trilostane 21
Polysulfated Glycosaminoglycan 21

Outcome Breakdown

Recovered/Normal
264 (50.7%)
Outcome Unknown
170 (32.6%)
Ongoing
54 (10.4%)
Recovered with Sequela
17 (3.3%)
Died
12 (2.3%)
Euthanized
4 (0.8%)

Gender Distribution

Female 252 (48.0%)
Male 249 (47.4%)
Unknown 19 (3.6%)
Mixed 5 (1.0%)

Reports by Year

Year Reports Trend
2010 3
2011 24
2012 48
2013 63
2014 59
2015 61
2016 46
2017 42
2018 31
2019 45
2020 29
2021 19
2022 9
2023 11
2024 22
2025 9
2026 4

Spaniel - King Charles: low death-coded share in the FDA CVM extract

Signature read: Spaniel - King Charles's 3.0% death-coded share is in the lower third of the ≥50-report cohort (median 4.8%). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, Spaniel - King Charles sits at #139 of 510 by report volume among all breeds and #115 of 298 among dog breeds, with 525 reports and 16 (3.0%) death-coded. On death-coded share among breeds with ≥50 reports, it ranks #234 of 275. Mean age at report: 5.0 years, average weight 9.0 kg (19.8 lbs).

Top reported signs: Vomiting (121), Emesis (81), Lethargy (see also Central nervous system depression in 'Neurological') (77). Most-referenced drug: Milbemycin Oxime + Spinosad (142 reports), followed by Ivermectin + Pyrantel As Pamoate Salt (70) and Afoxolaner (65).

Outcome coding on 521 status-recorded reports is dominated by Recovered/Normal (50.7%). Annual submissions ranged 3-2,026 across 17 years on file.

Dog Breeds With a Similar Report Volume

Showing 6 of 297 dog breeds in our dataset, ranked by closest report volume.

Nationwide breeds with similar profiles

High-volume peer sets for Spaniel - King Charles drawn from openFDA outside the Dog family so the neighborhoods are not species containment (the similar-volume list above stays within species).

Similar death-coded share

Nearest other-species breeds with ≥50 reports (3.0% death-coded here).

Similar average weight

Nearest other-species breeds by reported average weight (9.0 kg here).

What to do with this dog

A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.

Frequently Asked Questions

How many FDA adverse event reports involve Spaniel - King Charles?
There are 525 adverse event reports involving Spaniel - King Charles in the FDA database, of which 16 were death-coded (3.0% of those reports). That is a share of REPORTED events, not a mortality rate for the breed: adverse events reach the FDA when something goes wrong, so the denominator is reports, never the population of animals. According to the same FDA CVM extract, Spaniel - King Charles ranks #139 of 510 by report volume among all breeds PlainBreed indexes (#115 of 298 among dog breeds).
Where does Spaniel - King Charles sit among other breeds in PlainBreed's corpus?
According to FDA CVM report volume, Spaniel - King Charles is #139 of 510 breeds indexed on PlainBreed (same ordering as the most-reported-breeds ranking). Inside Dog, it is #115 of 298. Among breeds with at least 50 reports, its death-coded share ranks #234 of 275 (same cohort as highest-death-rate). These are placement ranks in the reporting corpus, not clinical risk scores.
What are the most common adverse reactions reported for Spaniel - King Charles?
The most commonly reported adverse reactions for Spaniel - King Charles are Vomiting (121 reports), Emesis (81 reports), Lethargy (see also Central nervous system depression in 'Neurological') (77 reports), Diarrhoea (68 reports), Digestive tract disorder NOS (36 reports).
What drugs are most frequently associated with Spaniel - King Charles adverse events?
The drugs most frequently referenced in Spaniel - King Charles adverse event reports are Milbemycin Oxime + Spinosad (142 reports), Ivermectin + Pyrantel As Pamoate Salt (70 reports), Afoxolaner (65 reports), Spinosad (46 reports), Fluralaner Chew Tablets (25 reports).
What is the average age of Spaniel - King Charles in adverse event reports?
The average age of Spaniel - King Charles at the time of adverse event reports is 5.0 years, with an average weight of 9.0 kg (19.8 lbs).

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Spaniel - King Charles (Dog), extract as of July 2026 extract. 525 reports · 16 death-coded (3.0% of reports, not a mortality rate) · #139 of 510 by volume.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →